Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial

Clinical Cancer Research

Volumn 12, Issue 3 II, 2006, Pages

  Hilsenbeck, Susan G ^a   Osborne, C Kent ^a   Brown, Myles ^b   Ingle, James ^b   Come, Steven ^b   Kumar, Rakesh ^b   Dowsett, Mitch ^b   Buzdar, Aman ^b   Winer, Eric ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Baylor College of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER MODEL; CONFERENCE PAPER; FOLLOW UP; HUMAN; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; RECURRENCE RISK;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMPUTER SIMULATION; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 32944467692     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2123     Document Type: Conference Paper

References (16)

1. Dowsett M; ATAC Trialists. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. In: San Antonio Breast Cancer Symposium, San Antonio, Texas; 2003.
2. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
3. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
4. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7.
5. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
6. Goss PE, Ingle JN, Martino S. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
7. Boccardo FM, Rubagotti A, Puntoni M, et al. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC) Updated results of the Italian tamoxifen anastrazole (ITA) trial. 2005 ASCO annual meeting proceedings. J Clin Oncol (Suppl) 2005;23:10s.
8. Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). 2005 ASCO annual meeting proceedings. J Clin Oncol (Suppl) 2005;23:10s.
9. Thurlimann BJ, Keshaviah A, Mouridsen H, et al. BIG1-98: randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for post-menopausal women with receptor-positive breast cancer. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol (Suppl) 2005;23:6s.
10. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.
11. Gross GE, Clark GM, Chamness GC, McGuire WL. Multiple progesterone receptor assays in human breast cancer. Cancer Res 1984;44:836-40.
12. Massarweh S, Osborne CK, Wakeling AE, Schiff R. Tamoxifen resistance in a breast cancer xenograft model coincides with a switch from an ER+/PgR+ to an ER+/PgR- phenotype accompanied by EGFR/HER2 activation. In: San Antonio Breast Cancer Symposium, San Antonio: 2004.
13. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV. Insulin-like growth factor-1 inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003;17:575-88.
14. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
15. Burstein HJ, Winer EP, Kuntz KM, Weeks JC, Punglia RS. Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: a decision analysis for biological subsets of tumors. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol (Suppl) 2005;23:11s.
16. Cuzick J, Howell A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of post-menopausal hormone receptor-positive breast cancer. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol (Suppl) 2005;23:43S.